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Differentiation of smooth muscle cells is accompanied by the transcriptional activation of an array of
muscle-specific genes controlled by serum response factor (SRF). Myocardin is a cardiac and smooth muscle-
specific expressed transcriptional coactivator of SRF and is sufficient and necessary for smooth muscle gene
expression. Here, we show that myocardin induces the acetylation of nucleosomal histones surrounding
SRF-binding sites in the control regions of smooth muscle genes. The promyogenic activity of myocardin is
enhanced by p300, a histone acetyltransferase that associates with the transcription activation domain of
myocardin. Conversely, class II histone deacetylases interact with a domain of myocardin distinct from the
p300-binding domain and suppress smooth muscle gene activation by myocardin. These findings point to
myocardin as a nexus for positive and negative regulation of smooth muscle gene expression by changes in
chromatin acetylation.
Smooth muscle cells (SMCs) are essential for the formation
and function of the cardiovascular, respiratory, genitourinary,
and digestive systems. Differentiation of SMCs is accompanied
by the transcriptional activation of a set of genes whose prod-
ucts mediate the unique contractile, structural, and metabolic
properties of the smooth musculature. Nearly every smooth
muscle gene analyzed to date is controlled by one or more
binding sites for serum response factor (SRF), a widely ex-
pressed MADS (MCM1, Agamous, Deficiens, SRF) box tran-
scription factor (reviewed in reference 31). SRF binds as a
homodimer to a DNA consensus sequence known as a CArG
box [CC(A/T)6GG], which is found in the control regions of
muscle-specific genes, as well as genes that are induced by
growth factor signaling (34, 38). The specific genes activated by
SRF are determined by the availability of positive and negative
cofactors, as well as intracellular signals (42). The related
MADS box factor myocyte enhancer factor 2 acts in a similar
manner to control muscle- and signal-inducible gene expres-
sion (3).
Myocardin is an SRF cofactor expressed specifically in
smooth and cardiac muscle lineages throughout embryonic
development and adulthood (44; reviewed in reference 45).
Myocardin belongs to the SAP (SAF-A/B, Acinus, PIAS) do-
main family of transcription factors, which has been implicated
in chromatin dynamics (2), and stimulates SRF-dependent
transcription by interacting with the MADS box of SRF and
providing its strong transcription activation domain (TAD)
(44). Remarkably, forced expression of myocardin in fibro-
blasts is sufficient to activate the smooth muscle differentiation
program (8a, 10, 48, 52). Consistent with its potential role as a
dominant activator of smooth muscle gene expression, knock-
out mice lacking myocardin die during mid-embryogenesis
from a lack of differentiated vascular SMCs and consequent
lethal cardiovascular abnormalities (25). Myocardin also reg-
ulates cardiac gene promoters in an SRF-dependent manner,
and expression of a dominant negative mutant form of myo-
cardin in Xenopus embryos can prevent heart formation (44).
However, forced expression of myocardin in fibroblasts in cul-
ture does not result in activation of endogenous cardiac genes,
suggesting that other factors are required for cardiac gene
expression or that endogenous inhibitors suppress cardiogenic
activity in this assay. In addition to myocardin, other SRF
cofactors, including CRP1 and CRP2, appear to play important
roles in regulating CArG-dependent smooth muscle gene ex-
pression (6).
Previous studies have suggested the involvement of chroma-
tin acetylation-deacetylation in the control of smooth muscle
gene expression (20, 28, 36). Histone acetylation, which is
catalyzed by histone acetyltransferases (HATs), promotes gene
transcription by destabilizing chromatin structure and facilitat-
ing access of transcriptional complexes to their target genes
(reviewed in reference 19). Among the best-characterized
HATs are p300 and CREB-binding protein (CBP), which act
as bridging factors between transcription factors and other
components of the transcriptional machinery and as targets for
several intracellular signaling pathways that stimulate tran-
scription (reviewed in references 5 and 13). While some tran-
scription factors rely on the HAT activity provided by p300/
CBP (and other HATs) to activate transcription, others
possess intrinsic HAT activity.
The gene-activating function of HATs is antagonized by the
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activity of histone deacetylases (HDACs), which deacetylate
nucleosomal histones, thereby promoting chromatin conden-
sation (43). Mammalian HDACs can be categorized into three
classes based on homology to yeast HDACs. Class I HDACs,
which include HDAC1, -2, and -3, are widely expressed and
contain simply a catalytic domain. Class II HDACs (HDAC4,
-5, -7, and -9) exhibit tissue-restricted expression patterns and
contain a bipartite structure with a C-terminal catalytic domain
and an N-terminal extension that mediates associations with a
variety of positive and negative cofactors. Class III HDACs are
NAD dependent and related to yeast Sir2.
The ability of myocardin to activate smooth muscle genes
that are otherwise silent in non-muscle cells suggests that myo-
cardin is able to convert smooth muscle genes from a repressed
to a transcriptionally active state. Here, we show that myocar-
din induces the acetylation of nucleosomal histones surround-
ing SRF-binding sites in the promoters of smooth muscle
genes. Acetylation of smooth muscle genes is mediated by the
association of myocardin with p300, which stimulates myocar-
din activity. The promyogenic activity of myocardin is counter-
acted by class II HDACs, which also interact with myocardin
and repress its activity. These opposing influences of HATs
and HDACs on myocardin activity provide a mechanism for
modulation of the smooth muscle differentiation program and
point to myocardin as a regulator of chromatin configurations
of smooth muscle genes and an integrator of positive and
negative influences on smooth muscle differentiation.
MATERIALS AND METHODS
Cell culture and transfection assays. Transfection of COS and 10T1/2 cells
and luciferase assays were performed as previously described (26, 44). Unless
otherwise indicated, 100 ng of reporter plasmid and 100 ng of each activator
plasmid were used. The total amount of DNA per well was kept constant by
adding the corresponding amount of expression vector without a cDNA insert.
All of the transfection experiments were repeated at least twice in duplicate.
Values are expressed as means  standard deviations.
Myocardin and HDAC expression vectors have been previously described (26,
44). The p300 expression vectors were obtained from Cheol Yong Choi
(Sungkyunkwan University, Seoul, South Korea), Tso-Pang Yao (Duke Univer-
sity), and Wei Gu (Columbia University). The E1A expression plasmid was a gift
of Tso-Pang Yao and Lishan Su (University of North Carolina). Myocardin and
HDAC5 deletion mutant proteins were generated through PCR-based mutagen-
esis with the QuikChange kit from Stratagene. All mutations were confirmed by
DNA sequencing. The SM22-luciferase reporter contained the 1,434-bp pro-
moter (24), and the ANF-luciferase reporter contained the 638-bp promoter of
the atrial natriuretic factor (ANF) gene (41). The 4  SM22-CArG-luciferase
reporter has been previously described (7). CMV-lacZ was included as an inter-
nal control for variations in transfection efficiency. All of the other reporters used
have been described previously.
GST protein-binding assays. A plasmid encoding a glutathione S-transferase
(GST) fusion protein was transformed into BL21-codon plus cells (Stratagene).
The cells were grown at 37°C in 2 YT medium to an optical density of 1.0.
Isopropyl--D-thiogalactopyranoside (IPTG; 50 M) was then added to the
culture to induce protein expression. After being shaken at room temperature
for 4 to 6 h, the cells were harvested and the GST protein was purified with
glutathione beads in accordance with the Amersham procedure.
Proteins translated in vitro were labeled with [35S]methionine with a TNT T7
reticulocyte lysate system (Promega). Glutathione beads conjugated with 1 g of
protein were incubated with 10 l of TNT product at 4°C for 2 h in 500 l of
GST-binding buffer (20 mM Tris [pH 7.3], 150 mM NaCl, 0.5% NP-40, protease
inhibitor cocktail from Roche, 1 mM phenylmethylsulfonyl fluoride [PMSF]).
The beads were washed three times with GST-binding buffer. Fifty microliters of
sodium dodecyl sulfate (SDS) loading buffer was then added to the beads. After
boiling, 20 l was loaded onto an SDS-polyacrylamide gel electrophoresis
(PAGE) gel and analyzed by autoradiography.
Coimmunoprecipitation assays. COS cells were transiently transfected with
plasmids encoding the epitope-tagged myocardin, HDAC4, HDAC5, and p300
proteins as indicated in the figure legends with FuGENE 6 reagent (Roche
Molecular Biochemicals). Cells were harvested 48 h after transfection in lysis
buffer composed of phosphate-buffered saline (PBS) containing 0.5% Triton
X-100, 1 mM EDTA, 1 mM PMSF, and complete protease inhibitors (Roche
Molecular Biochemicals). Following a brief sonication and removal of cellular
debris by centrifugation, epitope-tagged proteins were precipitated with antibod-
ies as indicated and protein A/G beads (Santa Cruz). The bound proteins were
washed five times with lysis buffer, resolved by SDS-PAGE, and transferred to
polyvinylidene difluoride membranes (Bio-Rad). Membranes were immunoblot-
ted with antibodies as indicated, and proteins were visualized with a chemilumi-
nescence detection system (Santa Cruz).
Immunostaining. Immunostaining was performed as previously described
(30). To determine the cellular localization of myocardin and HDAC5, COS cells
were transfected with FLAG-tagged myocardin and Myc-tagged HDAC5 and
stained with anti-FLAG (mouse monoclonal M2; Sigma) and anti-Myc (rabbit
polyclonal; Santa Cruz) antibodies. Myogenic conversion assays with 10T1/2 cells
were performed as previously described (26, 48) except that Lipofectamine
reagent (Invitrogen) was used for transfection. Mouse anti-SM -actin mono-
clonal antibody (1A4; Sigma) was used to monitor smooth muscle gene induc-
tion.
We determined the efficiency of myogenic conversion by myocardin by co-
transfecting a CMV-lacZ expression vector with the FLAG-myocardin expres-
sion vector. Eighteen percent of lacZ-positive cells expressing myocardin also
express smooth muscle proteins at a detectable level. By comparison, 26% of
lacZ-positive cells expressing MyoD in transfection assays also express skeletal
muscle proteins at a detectable level. We do not know whether the cells that
express myocardin but not smooth muscle proteins express myocardin at a level
too low to activate the smooth muscle differentiation program or, alternatively,
whether smooth muscle proteins are expressed in cells below the level of detec-
tion by immunostaining.
Histone acetylation assays and HAT activity assays. COS cells were transiently
transfected with expression vectors encoding the FLAG-tagged myocardin dele-
tion mutant proteins as described above. Forty-eight hours later, cells were
harvested and proteins were immunoprecipitated with M2 anti-FLAG antibody-
agarose (Sigma). Histone acetylation was assayed as previously described (35).
Protein A-agarose beads were washed twice with HAT buffer (50 mM Tris [pH
8.0], 10% glycerol, 1 mM PMSF), followed by incubation in 30 l HAT buffer
containing 1 mM dithiothreitol, 100 ng of trichostatin A (TSA) per l, 2 to 4 l
of 3H-labeled acetyl coenzyme A (5.3 l/mmol; Amersham), and 10 g of core
histones from Roche. After 1 h of incubation at 30°C, 2 SDS loading dye was
added to the reaction and the tubes were boiled at 95°C for 5 min. The proteins
were separated by SDS-PAGE. The gel was stained with Coomassie blue,
destained, and then incubated in Amplify solution (Amersham NAMP100) for 30
min at room temperature. After being dried, the gel was exposed to Amersham
Hyperfilm MP.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were carried out
with the ChIP assay kit from Upstate Biotech. Briefly, cellular proteins were
cross-linked with 1% formaldehyde at 37°C for 10 min. After being washed with
cold PBS twice, cells were scraped in 500 l of PBS and centrifuged at 5,000 rpm
in an Eppendorf 547C centrifuge. The pellets were then resuspended in 300 l
of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.1], protease
inhibitors). The lysate was sonicated three times for 10 s each to shear the DNA
into segments between 200 and 1,000 bp in length. After being centrifuged at
14,000 rpm in an Eppendorf 547C centrifuge for 10 min, the supernatants were
diluted 10 times with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2
mM EDTA, 16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, protease inhibitors).
One milliliter of the diluted lysate was then cleared with 10 g of salmon sperm
DNA and 20 l of protein A-agarose beads (Santa Cruz) at 4°C for 2 h. After
brief centrifugation to pellet the beads, the supernatant was incubated with 2 g
of specific antibodies overnight at 4°C. The next day, 10 g of salmon sperm
DNA and 40 l of protein A-agarose beads were added to the supernatant and
the mixture was incubated for 2 h. The beads were then washed sequentially with
low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl [pH 8], 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl [pH 8], 500 mM NaCl), and LiCl wash buffer
(0.25 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl
[pH 8.1]) for 5 min each. The beads were then washed three times with Tris-
EDTA, and the precipitates were then eluted twice with 250 l of elution buffer
(1% SDS, 0.1 M NaHCO3). Twenty microliters of 5 M NaCl was added to each
eluate, and the mixture was incubated at 65°C for 4 h to reverse cross-linking.
DNA fragments were then purified with a QIAquick spin column. The M2
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anti-FLAG antibody used was from Sigma, and the anti-acetyl histone H3 anti-
body used was from Upstate. The primers for the SM -actin promoter were
AGCAGAACAGAGGAATGCAGTGGAAGAGAC and CCTCCCACTCGC
CTCCCAAACAAGGAGC. The primers for the SM22 promoter were GGTC
CTGCCCATAAAAGGTTT and TGCCCATGGAAGTCTGCTTGG. Both
products contain two CArG boxes in the promoter regions. The primers for the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter were GCTCT
CTGCTCCTCCCTGTT and CAATCTCCACTTTGCCACTGC.
Detection of transcripts by reverse transcription (RT)-PCR. Total RNA was
isolated from cells with Trizol reagent and used as the template for RT with
primers specific for each transcript (Invitrogen) in accordance with the manu-
facturer’s instructions. The sequences of the primers used are available upon
request.
LacZ staining of mouse embryos. Embryos heterozygous for a lacZ knockin
allele into the HDAC5 locus (8) were fixed in formalin buffered with PBS,
embedded in paraffin, and sectioned at 5 m for histological examination. Sec-
tions were stained with hematoxylin and eosin and photographed under normal
bright-field microscopic conditions. LacZ staining was performed as previously
described (33). The expression pattern of the lacZ knockin allele faithfully
reflects the pattern of expression of the endogenous HDAC5 gene (8).
RESULTS
Myocardin induces histone acetylation at smooth muscle
gene promoters. Myocardin is a potent transcriptional activa-
tor that activates smooth muscle genes by tethering to CArG
boxes with SRF (44, 46). To determine the impact of myocar-
din on the acetylation state of nucleosomal histones associated
with smooth muscle gene promoters, we used ChIP assays to
monitor histone H3 acetylation in the vicinity of essential
CArG boxes in the SM -actin and SM22 promoters in 10T1/2
cells. In naı̈ve 10T1/2 cells, histone H3 was not acetylated on
these promoters. However, expression of myocardin, which
activates these and other smooth muscle genes, induced his-
tone H3 acetylation at these promoters (Fig. 1A). The gene for
GAPDH, which is expressed constitutively, did not show a
change in acetylation in response to myocardin. Thus, activa-
tion of endogenous smooth muscle target genes by myocardin
is accompanied by the acetylation of histones on the corre-
sponding gene promoters.
Modulation of myocardin activity by p300. The above find-
ings suggested that myocardin itself might be a HAT or that a
HAT might associate with myocardin. To test whether myo-
cardin possesses intrinsic HAT activity, we expressed it in bac-
teria and assayed the purified protein for its potential ability to
stimulate histone acetylation in vitro. Myocardin showed no
detectable HAT activity in this assay (data not shown). We
therefore tested whether myocardin activity might be modu-
lated by p300, a ubiquitous transcriptional coactivator with
intrinsic HAT activity. As reported previously (48), expression
of myocardin in 10T1/2 fibroblasts was sufficient to activate
smooth muscle gene expression measured by immunostaining
for SM -actin-positive cells. The promyogenic activity of myo-
cardin was augmented by p300, whereas p300 alone had no
effect on smooth muscle gene expression (Fig. 1B).
Cotransfection of expression plasmids encoding myocardin
and p300 into COS cells also resulted in synergistic and dose-
dependent activation of luciferase reporters linked to the
SM22 promoter, as well as the cardiac muscle-specific ANF
promoter (Fig. 2A), both of which are controlled by pairs of
CArG boxes (18, 21, 23). Similarly, p300 enhanced the ability
of myocardin to activate a luciferase reporter linked to four
tandem copies of a CArG box (Fig. 2A), but not a mutant
CArG box that cannot bind SRF (data not shown), demon-
strating that the stimulatory effect of p300 was mediated by the
SRF-binding site rather than sites for other transcription fac-
tors in the SM22 and ANF promoters. In the absence of myo-
cardin, p300 did not stimulate expression of CArG box-depen-
dent reporters, suggesting that its effects were directed at
myocardin, not SRF, which is expressed endogenously in COS
cells (Fig. 2A).
Because myocardin requires SRF to activate smooth and
FIG. 1. Acetylation of histones associated with smooth muscle gene promoters in response to myocardin and modulation of myocardin
myogenic activity by p300 and HDAC5. (A) 10T1/2 cells were transiently transfected with a FLAG-tagged myocardin expression vector () or a
control vector (), and ChIP assays were performed as described in Materials and Methods with primers for sequences associated with the genes
for SM -actin, SM22, and GAPDH. The amount of DNA in each sample (input) is shown at the left. Immunoprecipitations were performed
without primary antibody (no Ab) as a control and with anti-FLAG antibody and anti-acetyl histone H3 antibody, as indicated. (B) 10T1/2 cells
were transiently transfected with expression vectors encoding myocardin (0.1 g), p300 (0.5 and 1 g), or HDAC5 (0.2 and 0.5 g), as indicated,
and SM -actin protein expression was detected by immunostaining as described in Materials and Methods. Values are expressed as the relative
number of positive cells compared to the number in cultures transfected with myocardin alone, which was assigned a value of 100.
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cardiac muscle gene expression (44, 46) and SRF has been
reported to associate with the p300-related HAT CBP (37), we
sought to determine whether p300 could enhance the activity
of a GAL4-myocardin fusion protein, which functions indepen-
dently of SRF. As shown in Fig. 2B, p300 augmented the
transcriptional activity of GAL4-myocardin on a reporter con-
trolled by the GAL4 binding site, whereas p300 alone had no
effect on this reporter. The TAD of myocardin is located near
the C terminus, between residues 713 and 935, and its activity
is enhanced when it is removed from the remainder of the
protein (44). The transcriptional activity of the TAD was also
enhanced by p300 (Fig. 2B). Together, these data suggest that
p300 acts through the TAD of myocardin to stimulate tran-
scription of CArG box-dependent cardiac and smooth muscle
genes.
Class II HDACs repress the transcriptional activity of myo-
cardin. To further investigate the potential involvement of
histone acetylation-deacetylation in the activation of smooth
muscle gene expression by myocardin, we tested whether
HDACs affect the transcriptional activity of myocardin. In-
deed, HDAC5, a class II HDAC, potently suppressed the abil-
ity of myocardin to activate endogenous smooth muscle gene
expression in transfected 10T1/2 cells (Fig. 1B). HDAC4, an-
other class II HDAC, had an effect comparable to that of
HDAC5, whereas the class I HDACs HDAC1 and -3 had no
effect on myocardin activity in this assay (data not shown; see
below). HDAC5 also suppressed the expression of reporters
linked to the SM22 promoter and the multimerized CArG box
in the presence of myocardin, whereas HDAC1 did not affect
the activation of these reporters by myocardin (Fig. 2C).
To determine whether the repression of myocardin-depen-
dent transcription by HDAC5 was mediated directly by repres-
sion of myocardin activity or indirectly by repression of SRF or
another factor, we tested if HDAC5 could repress the tran-
scriptional activity of myocardin fused to the GAL4 DNA-
binding domain (Fig. 2D). HDAC5 strongly suppressed acti-
vation of the GAL4-dependent reporter by myocardin fused to
GAL4. As in the other assays, HDAC1 did not repress the
transcriptional activity of myocardin (Fig. 2D). The transcrip-
tional activity of myocardin was dependent on the relative
levels of p300 and HDAC5 such that increasing the relative
level of p300 could counteract the repressive effect of HDAC5
and vice versa (Fig. 2E). We conclude that p300 and HDAC5
exert opposing influences on smooth muscle gene expression,
at least in part by stimulating and suppressing, respectively, the
activity of myocardin.
Expression of HDACs in SMCs. To determine which class II
HDACs are expressed in A7r5 SMCs, we performed RT-PCR
assays with primers specific for each HDAC transcript. As
shown in Fig. 3A, multiple class I and II HDACs were ex-
pressed in A7r5 cells. The class II HDACs HDAC4, -5, and -7
were expressed at comparable levels.
We also examined the expression of HDAC5 in mouse em-
bryos at embryonic day 12.5 by monitoring the expression of a
FIG. 2. Modulation of myocardin transcriptional activity by p300 and HDAC5. (A) COS cells were transiently transfected with expression
vectors encoding myocardin (0.1 g) and p300 (0.5 and 1 g) and the indicated luciferase reporters as described in Materials and Methods.
(B) COS cells were transiently transfected with expression vectors encoding the GAL4 DNA-binding domain fused to amino acids 1 to 935
(GAL4-Myo) of myocardin (left graph) or 713 to 935 (GAL4-Myo-TAD) of myocardin, which encompasses the TAD (right graph) and p300 (1
g) and a UAS-luciferase reporter. (C) COS cells were transiently transfected with expression vectors encoding myocardin and HDACs (0.1, 0.2,
and 0.5 g) and the indicated luciferase reporters. (D) COS cells were transiently transfected with expression vectors encoding the GAL4
DNA-binding domain fused to amino acids 1 to 935 (GAL4-Myo) of myocardin, HDAC5 (0.1 and 0.5 g), or HDAC1 (0.1 and 0.5 g) and a
UAS-luciferase reporter. (E) COS cells were transiently transfected with expression vectors encoding myocardin (0.2 g), p300 (1 g), HDAC5
(0.5 g), and increasing amounts of p300 (0.5, 1, 2, and 4 g) and HDAC5 (0.5, 1, and 2 g), respectively, as indicated, and the SM22-luciferase
reporter.
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lacZ reporter introduced into the gene for HDAC5 by homol-
ogous recombination (8). Expression of the gene for HDAC5
was readily detectable in the smooth muscle layer of the dorsal
aorta, as well as in the esophagus and trachea, at this stage
(Fig. 3B). The level of expression of the lacZ marker in these
smooth muscle tissues was comparable to that in the myocar-
dial layer of the heart (Fig. 3B), where HDAC5 has been
shown to regulate cardiac growth and maturation (8).
Interaction of myocardin and p300. In order to determine
whether the stimulation of myocardin activity by p300 resulted
from a direct interaction between the proteins, we performed
coimmunoprecipitation assays with transiently transfected
COS cells with epitope-tagged proteins. As shown in Fig. 4, an
interaction between myocardin and p300 was readily detected.
With a series of myocardin deletion mutant proteins, we
mapped the domains responsible for this protein-protein in-
teraction (Fig. 4A and B).
Myocardin interacts with SRF through a basic and glu-
tamine-rich domain near the N terminus (44, 47). The SAP
domain of myocardin is not required for interaction with SRF
or for transcriptional activity, but it appears to discriminate
among different target genes since its deletion abolishes the
responsiveness of some genes, but not others, to myocardin
(44). Deletion of N-terminal sequences of myocardin up to
amino acid 713, removing the conserved N-terminal, basic,
glutamine-rich, and SAP domains, did not affect interaction
with p300. However, deletion of sequences between amino
acid 713 and the C terminus abolished this interaction. There-
fore, the TAD of myocardin, which was sufficient to confer
transcriptional responsiveness to p300, was necessary and suf-
ficient for interaction with p300.
We further examined the association of myocardin with
HAT activity by immunoprecipitating myocardin from trans-
fected cells and assaying for HAT activity in vitro with purified
histones as substrates. As shown in Fig. 4C, HAT activity was
associated with myocardin. With a series of myocardin deletion
mutant proteins, we found that residues 129 to 713 were devoid
of activity, whereas the C-terminal TAD (residues 552 to 935
or 713 to 935) was associated with HAT activity (Fig. 4C).
Given that p300 is ubiquitous and interacts with this region of
myocardin, it is likely to account, at least in part, for the
associated HAT activity, although other HATs could also be
involved. Together, these findings suggest that myocardin re-
cruits p300 and its HAT activity to the chromosomal location
of smooth muscle genes through a direct protein-protein in-
teraction.
Mapping of the myocardin-binding domain of p300. To de-
fine the region of p300 that interacts with myocardin, we per-
formed GST fusion protein pull-down assays. GST fused to the
myocardin TAD (residues 713 to 935) was immobilized on
glutathione-agarose beads and incubated with portions of p300
translated in vitro. As shown in Fig. 5, the amino-terminal
region of p300 (residues 1 to 670) specifically interacted with
myocardin, whereas no interaction was detected between other
regions of p300 (residues 671 to 1194 or 1135 to 2414) and
myocardin. As a negative control, GST alone or the amino
terminus of myocardin (residues 128 to 513) fused to GST was
used in the pull-down assays; no p300 binding to either of these
proteins was detected (Fig. 5 and data not shown), indicating
that the interaction between p300 and the C-terminal TAD of
myocardin was specific. Further mapping experiments demon-
strated that a region between residues 451 and 670 of p300,
which includes the previously identified CREB-binding do-
main (5), specifically interacted with myocardin (Fig. 5). To-
gether, these data demonstrate that myocardin and p300 di-
rectly interact in vivo and in vitro and that this interaction is
mediated by the TAD of myocardin and the CREB-binding
domain of p300.
E1A blocks the effects of p300 on myocardin-dependent
transcription. The above data demonstrated that p300 was
able to stimulate myocardin transcriptional activity through
direct protein-protein interaction. In order to test if p300 ac-
tivity was required for myocardin-dependent gene activation,
we used E1A, a p300 antagonist, to block p300 activity. The
adenovirus E1A protein can specifically bind to the C-terminal
region of p300 and repress its transcriptional activity (1, 4, 17).
To investigate whether E1A could disrupt the stimulatory ef-
fect of p300 on myocardin-dependent target genes, we per-
formed reporter assays as described above in the presence and
absence of an E1A expression plasmid. As shown in Fig. 6A,
E1A interfered with myocardin’s ability to activate the SM22
promoter, and it blocked activity of myocardin fused to the
GAL4 DNA-binding domain. E1A also blocked activation of
endogenous smooth muscle genes in 10T1/2 cells by myocardin
(Fig. 6B). Similarly, expression of E1A in the A7r5 and PAC-1
SMC lines extinguished the expression of smooth muscle genes
(data not shown). These findings support the conclusion that
p300 is critical to the promyogenic activity of myocardin.
FIG. 3. HDAC expression in SMCs. (A) Transcripts for the indi-
cated HDACs were detected by RT-PCR with RNA isolated from
A7r5 cells. Transcripts for calponin and ANF were used as markers of
smooth and cardiac muscles, respectively, and GAPDH was detected
as an internal control for RNA integrity and loading. (B) Embryonic
day 12.5 mouse embryos heterozygous for a targeted HDAC5 allele in
which lacZ was inserted in frame with the HDAC5 coding region were
stained for lacZ expression. Histological sections were cut and visual-
ized by bright-field microscopy; LacZ staining is indicated in pink. a,
atrium; ao, aorta; e, esophagus; t, trachea.
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Direct interaction of myocardin and HDAC5 and mapping
of the domains that mediate their interaction. We next inves-
tigated whether myocardin and class II HDAC proteins inter-
act by coimmunoprecipitation assays with transfected COS
cells. As shown in Fig. 7, myocardin specifically interacted with
HDAC4 and HDAC5, whereas another transcriptional repres-
sor, COOH-terminal binding protein (CtBP), did not interact
with myocardin (Fig. 7B). Myocardin also did not interact with
HDAC1 (data not shown), consistent with the failure of
HDAC1 to suppress myocardin activity. Myocardin and
HDAC5 colocalized precisely to the same intranuclear regions
in transfected COS cells (Fig. 7C), consistent with the possible
direct interaction of these two proteins in vivo.
The domains of myocardin and HDAC5 that mediate their
interaction were mapped by coimmunoprecipitation assays
with a series of myocardin and HDAC5 deletion mutant pro-
teins (Fig. 7A and D). Myocardin deletion mutant proteins
lacking N-terminal residues up to amino acid 268 interacted
with HDAC5, whereas a mutant protein lacking the first 328
amino acids failed to interact with HDAC5. Deletion mutant
proteins lacking residues C terminal to amino acid 348 also
retained the ability to interact with HDAC5. Thus, in contrast
FIG. 4. Mapping of the region of myocardin that interacts with p300. (A) Schematic diagram of myocardin and the mutant forms used to map
the p300-binding domain. NT, not tested. (B) Coimmunoprecipitation assays. COS cells were transiently transfected with expression vectors
encoding FLAG-tagged myocardin deletion mutant proteins and hemagglutinin (HA)-tagged p300. Myocardin proteins were immunoprecipitated
(IP) from cell lysates with a monoclonal anti-FLAG antibody, and coimmunoprecipitating HA-tagged p300 was detected by immunoblotting (IB)
with a polyclonal anti-HA antibody (top part). The expression of myocardin proteins was revealed by an anti-FLAG antibody (bottom part). NS,
nonspecific background. (C) COS cells were transiently transfected with expression vectors encoding the indicated myocardin deletion mutant
proteins, and immunoprecipitates were assayed for HAT activity in the presence of purified histones and 3H-labeled acetyl coenzyme A, followed
by SDS-PAGE, as described in Materials and Methods.
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to p300, which interacted with the TAD of myocardin, HDAC5
interacted with a distinct region near the N terminus (between
amino acids 268 and 328). Because the HDAC5-binding region
of myocardin overlapped the SRF-binding region, we consid-
ered the possibility that HDAC5 might repress myocardin ac-
tivity by displacing it from SRF. However, HDAC5 did not
disrupt the formation of a ternary complex between SRF and
myocardin in gel mobility shift assays (data not shown). The
ability of HDAC5 to inhibit the activity of GAL4-myocardin on
an upstream activating sequence (UAS)-luciferase reporter
also discounts such a potential displacement mechanism for
repression by HDAC5.
With a series of HDAC5 deletion mutant proteins, we found
that mutant proteins lacking sequences N terminal to amino
acid 153 retained the ability to interact with myocardin (Fig.
8A and B). However, further deletion to amino acid 201 com-
pletely abolished this interaction, suggesting that the region
between residues 153 and 201 is essential for HDAC5 to in-
teract with myocardin. Deletions from the C terminus revealed
that residues downstream of amino acid 300 are not required
for interaction with myocardin (Fig. 8A and B). We conclude
that a myocardin-binding domain lies between amino acids 153
and 201 of HDAC5.
There was a direct correlation between the abilities of
HDAC5 deletion mutant proteins to interact with myocardin
and repress its activity. Thus, only those HDAC5 deletion
mutant proteins that contained amino acids 153 to 201 were
able to interact with and repress myocardin. It is notable that
the C-terminal region of HDAC5, which contains the catalytic
domain, was not required for repression of myocardin activity
(Fig. 8C).
Simultaneous interaction of p300 and HDAC5 with myocar-
din. The finding that p300 and HDAC5 interact with separate
regions of myocardin suggested the possibility that they might
simultaneously associate with myocardin. Indeed, in coimmu-
noprecipitation experiments with FLAG-tagged myocardin,
FIG. 5. Mapping of the region of p300 that interacts with myocardin. (A) Schematic diagram of p300 and mutant forms used to map the
myocardin-binding domain. CH1, CH2, CH3, cysteine- and histidine-rich domains; BD, bromodomain; NHR, nuclear hormone receptor binding
region; GRR, glutamine-rich region. (B) GST pull-down assays. GST-myocardin (amino acids 713 to 935) fusion protein or GST alone was
incubated with [35S]methionine-labeled portions of p300 as described in Materials and Methods. Associated proteins were resolved by SDS-PAGE
and analyzed by autoradiography (top and middle parts). In the bottom part, 10% of the [35S]methionine-labeled p300 protein was applied directly
to the gel to control for input.
FIG. 6. Blockade of myocardin-induced smooth muscle gene ex-
pression by E1A. (A) 10T1/2 cells were transiently transfected with
expression vectors encoding myocardin and E1A and an SM22-lucif-
erase reporter (left part) or GAL4-myocardin and E1A and a UAS-
luciferase reporter (right part), as indicated. (B) 10T1/2 cells were
transiently transfected with expression vectors encoding myocardin
and E1A, as indicated, and cells were stained for expression of SM
-actin. A representative cell expressing SM -actin is shown (left
part), as is blockade of myocardin-induced SM -actin expression by
E1A (right part). Values are expressed as the relative number of
positive cells compared to the number in cultures transfected with
myocardin alone, which was assigned a value of 100.
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HA-tagged p300, and Myc-tagged HDAC5, we found that both
p300 and HDAC5 could be coimmunoprecipitated in the pres-
ence, but not in the absence, of myocardin (Fig. 9). Thus, the
balance between the stimulatory and repressive influences of
p300 and HDAC5, respectively, is likely to dictate the tran-
scriptional activity of myocardin.
Effects of TSA on myocardin activity. To further explore the
involvement of histone acetylation-deacetylation in the con-
trol of myocardin activity, we tested the effect of the HDAC
inhibitor TSA on the transcriptional activity of myocardin.
As shown in Fig. 10A, TSA enhanced the transcriptional
activity of the full-length myocardin protein fused to GAL4.
In contrast, TSA treatment did not further enhance the
activity of the myocardin TAD (data not shown). TSA also
enhanced the expression of the SM22 promoter in the pres-
ence of myocardin to a level similar to that of myocardin
plus p300 (Fig. 10B). Furthermore, cotransfecting TSA-
treated cells with p300 did not increase myocardin activity
FIG. 7. Mapping of the region of myocardin that interacts with HDAC5. (A) Schematic diagram of myocardin and the mutant forms used to
map the HDAC5-binding domain. (B) Coimmunoprecipitation assays. COS cells were transiently transfected with expression vectors encoding
FLAG-tagged myocardin and Myc-tagged HDAC4, HDAC5, and CtBP1. Myc-tagged proteins were immunoprecipitated (IP) from cell lysates with
a polyclonal anti-Myc antibody, and coimmunoprecipitating myocardin was detected by immunoblotting (IB) with a monoclonal anti-FLAG
antibody (top part). The membrane was reprobed with anti-Myc antibody to reveal the total amount of Myc-tagged proteins (bottom part).
(C) Immunostaining of myocardin and HDAC5. COS cells were transiently transfected with expression vectors for FLAG-tagged myocardin and
Myc-tagged HDAC5, and the subcellular distribution of the proteins was determined by immunostaining as described in Materials and Methods
(top and middle parts). Overlay of the individual staining patterns reveals a precise correlation between the intranuclear distribution of myocardin
and that of HDAC5 (bottom part). (D) Coimmunoprecipitation assays. COS cells were transiently transfected with expression vectors encoding
FLAG-tagged deletion mutant myocardin proteins and Myc-tagged HDAC5. Myc-tagged HDAC5 was immunoprecipitated from cell lysates with
a polyclonal anti-Myc antibody, and coimmunoprecipitating myocardin proteins were detected by immunoblotting with a monoclonal anti-FLAG
antibody (top part). The expression levels of HDAC5 (middle part) and myocardin mutant proteins (lower part) were revealed by Western blot
assays with the indicated antibodies.
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further (Fig. 10B). Together, these data suggest that the
primary function of p300 on myocardin is to relieve the
repressive effect of HDAC5 on myocardin. Because the cat-
alytic domain of HDAC5 was not required for repression
but HDAC inhibition with TSA stimulated myocardin activ-
ity, we conclude that the effects of TSA are likely to be
directed at class I HDACs, which can associate with HDAC5
(12, 43).
Repression of smooth muscle differentiation by HDAC5. To
further investigate the potential involvement of class II
HDACs in the suppression of smooth muscle gene expres-
sion, we examined the effect of HDAC5 on the expression of
smooth muscle genes in the A7r5 and PAC-1 SMC lines. As
shown in Fig. 11, HDAC5 reduced the expression of smooth
muscle genes in these cell lines. Mutant forms of HDAC5
that were unable to interact with myocardin had no effect on
smooth muscle gene expression (data not shown). We con-
clude that HDAC5 suppresses smooth muscle gene expres-
sion by its association with myocardin on smooth muscle
target genes.
FIG. 8. Mapping of the regions of HDAC5 that interact with myocardin. (A) Schematic diagram of HDAC5 and the mutant forms used to map
the myocardin-binding domain. (B) Coimmunoprecipitation assays. COS cells were transiently transfected with expression vectors encoding
Myc-tagged HDAC5 deletion mutant proteins and FLAG-tagged myocardin. Myc-tagged HDAC5 deletion mutant proteins were immunopre-
cipitated (IP) from cell lysates with a polyclonal anti-Myc antibody, and coimmunoprecipitating myocardin was detected by immunoblotting (IB)
with a monoclonal anti-FLAG antibody (top parts). The membrane was reprobed with anti-Myc antibody to reveal the total amount of Myc-tagged
HDAC5 proteins (bottom parts). (C) COS cells were transiently transfected with expression vectors encoding myocardin and HDAC5 deletion
mutant proteins and the SM22 luciferase reporter.
FIG. 9. Simultaneous interaction of myocardin with p300 and
HDAC5. COS cells were transiently transfected with expression vec-
tors encoding hemagglutinin (HA)-tagged p300, FLAG-tagged myo-
cardin, and Myc-tagged HDAC5. FLAG-tagged myocardin was immu-
noprecipitated (IP) from cell lysates with a monoclonal anti-FLAG
antibody, and coimmunoprecipitating p300 was detected by immuno-
blotting (IB) with an anti-HA antibody (top part). The membrane was
then stripped and reprobed with anti-Myc antibody to reveal coimmu-
noprecipitating Myc-tagged HDAC5 proteins (second part from the
top). Cell extracts were probed with antibodies against HA, FLAG,
and Myc to detect p300, myocardin, and HDAC5, respectively (bottom
three parts).
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DISCUSSION
Differentiation of SMCs is accompanied by acetylation of
histones associated with smooth muscle gene promoters (28,
36). However, the mechanisms and transcriptional targets of
chromatin-modifying enzymes that influence smooth muscle
gene expression have remained elusive. The results of this
study demonstrate that myocardin induces the acetylation of
histones associated with smooth muscle target genes and that
p300 and HDAC5 stimulate and suppress, respectively, the
promyogenic transcriptional activity of myocardin. These find-
ings suggest that myocardin modulates the expression of its
target genes, at least in part, by recruiting HATs and HDACs
with consequent alterations in chromatin acetylation.
Stimulation of myocardin activity by p300. Our results show
that p300 associates specifically with the TAD of myocardin
and enhances myocardin activity. Although the closely related
HAT CBP has also been shown to interact with SRF to activate
c-fos gene expression (37), this interaction is apparently insuf-
ficient to activate endogenous smooth muscle genes since CBP
is expressed in a wide range of cell types in which smooth
muscle genes are not expressed. Similarly, overexpression of
p300 in 10T1/2 cells did not result in smooth muscle gene
expression in the absence of myocardin, suggesting that addi-
tional factors are required. It is also important to note that
both SRF and p300/CBP are ubiquitous, but smooth muscle
promoters are unacetylated in non-SMCs, which further dem-
onstrates that the potential interaction of SRF and p300/CBP
is unable to modify chromatin associated with smooth muscle
genes to a transcriptionally permissive state. In contrast, myo-
cardin is able to induce the acetylation of nucleosomal histones
associated with its target genes, which presumably is mediated
by its recruitment of p300. We speculate that activation of the
smooth muscle gene program may require a precise configu-
ration of transcriptional activators on the corresponding pro-
moters and that myocardin is required to orchestrate such a
configuration. Given that myocardin preferentially activates
promoters with two or more CArG boxes (44) and can form
homodimers or heterodimers with myocardin-related tran-
scription factors (MRTFs) (48) through its leucine zipper do-
main, perhaps it selectively activates smooth muscle target
genes by bridging SRF bound at multiple sites.
p300 has been shown to stimulate transcription through var-
ious mechanisms, including the bridging of sequence-specific
transcriptional activators to the basal transcription machinery,
the recruitment of accessory factors with HAT activity, and the
direct acetylation of histones and/or other transcription factors
via its intrinsic HAT activity (5, 13). Any of these mechanisms
could contribute to the synergistic activation of smooth muscle
gene expression by myocardin and p300.
p300 associates with other transcriptional regulators primar-
ily through three domains (5, 13). These include the amino-
terminal zinc finger domain CH1, which interacts with TBP,
RXR, STAT2, and others; the CREB-binding domain in the
middle of the protein, which facilitates the interaction with
CBP, YY1, c-Jun, BRCA1, and others; and the carboxyl-ter-
minal zinc finger domain CH3, which mediates the interaction
between p300 and GATA1, GATA4, MyoD, E1A, and others.
Our results identify the CREB-binding domain of p300 as the
region that interacts with myocardin. It will be of interest to
determine whether other p300-associated proteins, such as
CBP and YY-1, compete with myocardin for interaction with
this domain. It is notable in this regard that YY-1, which
functions as a transcriptional activator or repressor, binds to
the CArG box (14, 22, 32).
Although it is not sufficient to activate muscle gene expres-
sion by itself, p300 is essential for embryogenesis and cardiac
muscle differentiation (51). Because of an early embryonic
lethality, the involvement of p300 in smooth and skeletal mus-
cle development in vivo remains to be determined. Interest-
ingly, E1A, which specifically inhibits p300, has been shown to
suppress skeletal muscle differentiation by perturbing the ac-
tivity of the MyoD family of myogenic transcription factors
(49). Our results show that E1A represses myocardin activity
and smooth muscle gene expression, further implicating p300
in smooth muscle gene activation. The domain of p300 that
associates with E1A is distinct from the myocardin-binding
FIG. 10. Effects of TSA on myocardin activity. (A) COS cells were
transiently transfected with expression vectors encoding GAL4-myo-
cardin fusion protein and the UAS-luciferase reporter. Cells were
treated with 0.1 M TSA after transfection and harvested 48 h later for
determination of luciferase activity. (B) Effects of TSA on myocardin
and p300 transcriptional activity. COS cells were transiently trans-
fected with expression vectors encoding myocardin, p300, and the
SM22-luciferase reporter. Cells were treated with 0.1 M TSA after
transfection and harvested 48 h later for determination of luciferase
activity.
FIG. 11. Suppression of smooth muscle gene expression in A7r5
and PAC-1 cells by HDAC5. A7r5 cells were infected with adenovirus
encoding LacZ () or HDAC5 (), and smooth muscle gene expres-
sion was assayed by RT-PCR. PCR products were quantified by phos-
phorimager analysis, and values were expressed relative to the level of
expression of each transcript in lacZ virus-infected cells. SM-MLCK,
SM-myosin light chain kinase; SM-MHC, SM-myosin heavy chain.
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region, suggesting that E1A does not disrupt the smooth mus-
cle gene program by displacing myocardin from p300. E1A has
previously been shown to block p300 function by inhibiting its
HAT activity (1, 4, 17), suggesting that the HAT activity of
p300 is directly involved in the regulation of myocardin tran-
scriptional activity.
Repression of myocardin activity and smooth muscle differ-
entiation by HDAC5. In contrast to the interaction between
myocardin and p300, which stimulates myocardin activity, the
association of myocardin and class II HDACs strongly inhibits
myocardin activity. Suppression requires interaction of HDAC5
with myocardin, which is mediated by a segment in the N-terminal
extension of HDAC5 that tethers it to the N-terminal region of
myocardin. Surprisingly, however, the catalytic domain of
HDAC5 is not required for repression of myocardin activity. The
N-terminal domain of class II HDACs has also been shown to
repress myocyte enhancer factor 2 activity independently of the
catalytic domain (12, 40, 55, 56). This may be attributable to the
interaction of the N-terminal region with a variety of corepres-
sors, such as CtBP (56), as well as class I HDACs (12, 43).
The TAD of myocardin (residues 713 to 935) is approxi-
mately 50-fold more active than the full-length protein when
fused with a GAL4 DNA-binding domain (44), suggesting the
presence of inhibitory factors associated with the N terminus of
myocardin. The association of HDAC5 with the N terminus of
myocardin may contribute to the repressive influence of the
N-terminal sequences on the activity of the myocardin TAD.
The MADS box of SRF has recently been reported to inter-
act with HDAC4, with resultant repression of SRF activity (9).
While such an interaction could contribute to the repressive
effect of HDAC5 on myocardin activity, the ability of HDAC5
to repress transcriptional activity of a GAL4-myocardin pro-
tein demonstrates that SRF is not required for repression by
HDAC5. The facts that HDAC5 and -4 directly interact with
myocardin and such direct association is required for the re-
pression of myocardin further support our conclusion that
HDAC5-mediated repression of smooth muscle gene expres-
sion is the result of direct repression of myocardin transcrip-
tional activity, not through repression of other factors. More-
over, we believe that the interaction between HDAC4 and
SRF is substantially weaker than that between HDAC4 and
myocardin because in our experiments it was undetectable
under conditions in which HDAC4-myocardin interactions
were readily detectable (data not shown).
Recently, MyoD, a master transcriptional regulator of skel-
etal muscle differentiation, was shown to associate with p300
and HDAC1 (11, 27, 39, 53). MyoD apparently associates with
HDAC1 in undifferentiated myoblasts, where it is kept in a
silent state. However, when myoblasts begin to differentiate,
MyoD dissociates from HDAC1 and eventually partners with
HAT/pCAF to activate skeletal myogenesis (27). Our findings
suggest that similar mechanisms operate during smooth muscle
differentiation, with myocardin rather than MyoD serving as
the target of positive and negative chromatin remodeling en-
zymes.
Expression of HDACs in smooth muscle. Consistent with
their potential involvement in SMC differentiation, multiple
class I and II HDACs are expressed in the A7r5 SMC line. Our
results also document robust expression of HDAC5 in the
smooth muscle layer of the developing aorta during mouse
embryogenesis. Because myocardin target genes are expressed
in A7r5 cells and in the developing aorta at a time when
HDAC5 is also expressed, the repressive influence of HDAC
activity on myocardin must be overcome by counterregulatory
mechanisms in these settings. Given the sensitivity of class II
HDACs to calcium signals (29), it is interesting to speculate
that such signaling systems may be activated in A7r5 cells and
in the developing aorta, thereby favoring the promyogenic
influence of p300 (or other HATs) on myocardin.
It is also notable that HDAC5 null mice are viable and show
no overt SMC phenotype (8). Thus, we favor the interpretation
that HDAC5 may influence the onset of SMC differentiation
and/or participate in phenotypic remodeling of SMCs, but its
repressive influence seems unlikely to be essential for ho-
meostasis of SMCs. It is also conceivable that other class II
HDACs mask potential functions of HDAC5.
Modularity of myocardin. The antagonistic effects of p300
and HDAC5 on myocardin activity do not appear to result
from direct competition between those proteins for myocardin
interaction because p300 and HDAC5 bind to myocardin at
different regions (Fig. 12). This modular structure potentially
enables myocardin to recruit HDAC5 and/or p300 to CArG
box-containing promoters while being tethered to SRF on
DNA. Once in the vicinity of these control regions, HDAC5
and p300 can potentially exert negative or positive effects,
respectively, on gene expression. Modulation of the activities
of class II HDACs and p300 in response to intracellular signals
may provide additional specificity to their effects on myocardin
target genes.
Interestingly, the inhibitory effects of HDAC5 on myocardin
appear to be dominant, as overexpression of p300 cannot com-
pletely overcome the repressive influence of HDAC5 on myo-
cardin activity. We propose that the HDAC-mediated repres-
sion is probably the default pathway, whereas p300-mediated
activation may be used only when target genes need to be
activated.
Recently, we demonstrated that the ability of myocardin to
activate smooth muscle gene expression can be regulated
through competition between myocardin and Elk-1, a ternary
complex factor that interacts with the same region of SRF as
myocardin but represses SRF-dependent transcription (47).
Unlike the inhibition by HDAC5, which did not affect myocar-
din/SRF association, Elk-1 represses myocardin-dependent
smooth muscle gene expression by preventing the association
of myocardin with SRF.
Given the fact that myocardin and the other two MRTFs,
MRTF-A and -B, have the same structural organization as the
FIG. 12. Schematic diagram of protein interaction domains of myo-
cardin. Domains in myocardin for SRF, HDACs, and p300 interactions
are indicated. NTD, N-terminal domain; , basic domain; Q, glu-
tamine-rich domain; LZ, leucine zipper.
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conserved N-terminal, basic, Q-rich, and SAP domains, as well
as the C-terminal TAD (46), it is likely that MRTFs are also
targets for p300 and HDACs. However, unlike myocardin,
MRTF-A and -B are ubiquitously expressed during embryo-
genesis and adulthood. The specificity and biological signifi-
cance underlying the regulation of their transcriptional activity
by p300 and HDACs remains to be determined.
Implications for cardiovascular development and disease.
The modulation of myocardin activity by HATs and HDACs is
likely to play important roles in regulating smooth and cardiac
muscle gene expression during disease. For example, numer-
ous disease states, such as atherosclerosis, asthma, hyperten-
sion, and restenosis following angioplasty, are accompanied by
the dedifferentiation and inappropriate proliferation of SMCs.
In addition to its role in smooth muscle gene expression, myo-
cardin has been implicated in cardiac gene expression on the
basis of the ability of a dominant negative mutant form of
myocardin to disrupt heart formation in Xenopus embryos (44).
Myocardin is also a potent activator of the ANF promoter,
which is activated in the heart in response to stress signals.
Several recent studies have demonstrated the importance of
p300 and class II HDACs for hypertrophic growth of cardiac
myocytes, which is accompanied by activation of a fetal gene
program (8, 15, 16, 50, 54). The calcium-responsive phospha-
tase calcineurin and calcium/calmodulin-dependent protein ki-
nase are powerful transducers of hypertrophic stimuli in car-
diac myocytes and act by stimulating the activity of p300 and
repressing the activity of class II HDACs, with consequent
activation of stress-responsive cardiac genes such as ANF, a
myocardin target gene (reviewed in reference 29). Thus, it will
be of interest to determine whether p300 and class II HDACs
influence cardiac gene expression via their influences on myo-
cardin activity during cardiac development and disease.
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